Showing results (1931-1940 of 3,086) with videos related to

Sort By:
Pageof 309
Drug Safety|September 26, 2024
An Integrated Approach for Representing Knowledge on the Potential of Drugs to Cause Acute Kidney InjuryDaniel Fernández-Llaneza, Romy M P Vos, Joris E Lieverse, et al.
Drug Safety|September 12, 2024
Emergency Department Use of Heart Failure-Exacerbating Medications in Patients with Chronic Heart FailureMartin F Casey, Joy Hallmark, Patricia P Chang, et al.
Drug Safety|February 21, 2025
Effectiveness of Transformer-Based Large Language Models in Identifying Adverse Drug Reaction Relations from Unstructured Discharge Summaries in SingaporeYen Ling Koon, Yan Tung Lam, Hui Xing Tan, et al.
Drug Safety|February 20, 2025
Leveraging FDA Labeling Documents and Large Language Model to Enhance Annotation, Profiling, and Classification of Drug Adverse Events with AskFDALabelLeihong Wu, Hong Fang, Yanyan Qu, et al.
Drug Safety|August 19, 2024
A Comparison of Active Pharmacovigilance Strategies Used to Monitor Adverse Events to Antiviral Agents: A Systematic ReviewRenato Ferreira-da-Silva, Joana Reis-Pardal, Manuela Pinto, et al.
Drug Safety|March 30, 2006
Thalidomide use in the US : experience with pregnancy testing in the S.T.E.P.S. programmeKathleen Uhl, Edward Cox, Rose Rogan, et al.
Drug Safety|March 30, 2006
Influence of pharmacists' attitudes on adverse drug reaction reporting : a case-control study in PortugalMaria T Herdeiro, Adolfo Figueiras, Jorge Polónia, et al.
Drug Safety|July 29, 2006
Pharmacovigilance during the pre-approval phases: an evolving pharmaceutical industry model in response to ICH E2E, CIOMS VI, FDA and EMEA/CHMP risk-management guidelinesCraig G Hartford, Kasia S Petchel, Hani Mickail, et al.
Drug Safety|September 15, 2006
Disease-modifying antirheumatic drugs in pregnancy: current status and implications for the futureFokaline Vroom, Hermien E K de Walle, Mart A J F van de Laar, et al.
Drug Safety|September 15, 2006
Comparative performance of two quantitative safety signalling methods: implications for use in a pharmacovigilance departmentJune S Almenoff, Karol K LaCroix, Nancy A Yuen, et al.
Pageof 309